Codex DNA
San Diego
About Codex DNA
Codex DNA is a biology company helping researchers with the tools they need to securely design, code, and create synthetic DNA. The company is on a mission to help scientific researchers in both academic and commercial settings with the hardware, software, materials, and methodologies required to rapidly and accurately write large quantities of synthetic genes. To, in effect, build biology. Its gene synthesis portfolio reduces the turnaround time for synthesizing workflows from weeks and months to days and hours and includes the BioXp system, DNA services, Gibson Assembly reagents, and Vmax chemically competent cells. In addition to automating, speeding, and optimizing DNA design and synthesis, Codex DNA and the BioXp system ensure your designs stay in your hands, marrying speed and security for innovators in drug discovery, vaccine development, precision medicine, and beyond. Co-founded by Dan Gibson ’ the creator of the industry-standard Gibson Assembly methodology ’ Codex DNA is attempting nothing less than changing everything.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 101 – 250
- Estimated revenue: $10K – $50K
- Total funding: $25.0M
- Funding stage: IPO
- Last round: Series A (Sep 2019)
- Ticker: nasdaq:DNAY
- Website: codexdna.com
- Phone: +1 858 228 4115
Industries & Categories
Biotechnology, Chemical, Genetics, Life Science
Social Profiles
Canonical: https://fsome.com/organization/codex-dna-117020 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.